REGN13335

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Healthy VolunteersPulmonary Arterial Hypertension (PAH)

Phase 1

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

CompletedNCT06137482

Regeneron PharmaceuticalsHealthy Volunteers

Start: 2023-12-06End: 2025-02-11Updated: 2025-03-19

Phase 2

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

RecruitingNCT07318597

Regeneron PharmaceuticalsPulmonary Arterial Hypertension (PAH)

Start: 2026-05-06End: 2028-09-17Target: 99Updated: 2026-09-15

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension

Not yet recruitingCTIS2024-514754-79-00

Regeneron Pharmaceuticals Inc.Pulmonary Arterial Hypertension (PAH)

Target: 5Updated: 2026-03-18